Angelina Egorova

Prof. Angelina Egorova

Department of Oncology and Radiation Therapy, NI Pirogov Russian National Research Medical University, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Life
Verified
Journal Article
Open access
PDF file
IPIlya Pustinsky
Ilya Pustinsky
ADAnton Sergeevich Dvornikov
Anton Sergeevich Dvornikov
EKEkaterina Kiva
Ekaterina Kiva
SCSvetlana Chulkova
Svetlana Chulkova
AEAngelina Egorova
Angelina Egorova
SKSergey Kalinin
Sergey Kalinin
The clinical relevance of head and neck (H&N) tumors is related to the potential disfiguration of anatomical structures (by the tumor or surgical intervention), defining patients’ individual features and emotional expression, loss or restraint of vital structures functions, and untoward socio-economic sequelae. This study is aimed to improve clinical outcomes of cryosurgery in patients with H&N basal cell skin cancer by refining the indications for cryosurgical treatment. In this study, cryosurgery was used in 234 patients with different stages of cutaneous basal cell carcinoma (BCC) of the head, including 101 patients with T1 tumors, 86—with T2, 5—T3, and 42 patients with tumors relapsing after failure of preceding various treatment modalities. Post-cryosurgery recurrence rate in patients with stage I BCC was 2.7%, with stage II tumors—5.6% and 34.9%—in patients with recurred tumors. Re-recurrence after cryoablation of recurrent tumors correlated with the tumor baseline size. The best aesthetic and long-term clinical results were documented in patients with lesions <1 cm in size with clear boundaries. Thus, cryosurgery is the method of choice for the majority of stage I basal cell carcinomas of the head. For patients with advanced and recurrent skin cancer, cryosurgery is relevant in rare cases selected according to refined indications.

21 April 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EVE. F. Valiakhmetova
E. F. Valiakhmetova
OBO. I. Budanov
O. I. Budanov
SGS. K. Gorelyshev
S. K. Gorelyshev
NSN. K. Serova
N. K. Serova
LLL. A. Lasareva
L. A. Lasareva
ЮТЮ. Ю. Трунин
Ю. Ю. Трунин
Low grade gliomas (LGG) constitute 35-40% of all primary central nervous system (CNS) tumors in children, at least 10-12% of them affecting the optic pathway. The complexity of the localization and predominantly the diffuse type of growth of these tumors make the neurosurgical treatment not appropriate in most cases, which requires conservative treatment.Objective: to analyze the results of carboplatin and vincristine chemotherapy (CT) regime in children with optic pathway gliomas (OPG). The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. In the study was included patients registered at the Burdenko Neurosurgery Institute from January 1, 2003 till December 31, 2015 with optic pathway glioma from 0 to 18 years old that were treated with combined carboplatin and vincristine chemotherapy. All patients were divided into 2 groups: the first group included patients who had newly diagnosed OPG (group 1), the second group included patients with OPG with radiological progression following observation times (group 2). Evaluation of the response to treatment was carried out on the 24th week and after completion of treatment by delineation of each slice of the MRI images in OsiriX MD software (© Pixmeo Sari, Switzerland) with subsequent automatic volume calculation.Results: 104 patients were included in the analysis. 69 children were included to group 1, 35 patients in group 2. 60% of patients were boys, about a third of children were less than 18 months old, 17% of patients had Neurofibromatosis type I, 24% of patients had diencephalic cachexia. A biopsy of the tumor was performed in 76% of the patients, 54% of the patients had a piloid astrocytoma and 23% had a pilomixoid astrocytoma. The progression after the start of the chemotherapy was in 30 (28.9%) patients. 5-year event free survival (EFS) and overall survival (OS) were 58 ± 6% and 97 ± 2%, respectively. 5-year EFS was not statistically significantly different in patients of groups 1 and 2. According to our data, the age, histology of the tumor, the response to the 24th week of CT are independent prognostic factors.

19 June 2020 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
IGI. A. Gladilina
I. A. Gladilina
MSM. A. Shabanov
M. A. Shabanov
OKO. A. Kravets
O. A. Kravets
FZF. O. Zakhidova
F. O. Zakhidova
SIS. M. Ivanov
S. M. Ivanov
SCSvetlana Chulkova
Svetlana Chulkova
Постлучевые повреждения легких

6 December 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ISI. V. Savchenko
I. V. Savchenko
VBV. V. Breder
V. V. Breder
ISI. S. Stilidi
I. S. Stilidi
KLK. K. Laktionov
K. K. Laktionov
NKN. E. Kudashkin
N. E. Kudashkin
SCSvetlana Chulkova
Svetlana Chulkova
Biliary cancer is a group of tumors that develop from the epithelium of the intra- and extrahepatic bile ducts (cholangiocarcino-ma), as well as the gallbladder. For 10 years, chemotherapy based on a combination of gemcitabine and cisplatin has remained the standard of first-line therapy in patients with locally advanced or metastatic biliary cancer, resulting in a median overall survival of 11.7 months. With the progression of the disease on the first line, effective options did not previously exist. Attempts to use various chemotherapeutic regimens, both in monotherapy and in combination, have not been successful. In order not to leave the patient without treatment, fluoropyrimidines, their combinations with oxaliplatin or irinotecan, are empirically prescribed as follow-up therapy. In recent years, different subtypes of biliary tract cancer have been defined depending on the anatomical location and genetic and/or epigenetic aberrations. Especially for intrahepatic cholangiocarcinoma novel therapeutic targets have been identified, including fibroblast growth factor receptor gene fusions 2 (FGFR2) and isocitrate dehydrogenase 1 and 2 mutations (IDH1/2), with molecularly targeted agents having shown evidence of activity in this subgroup of patients. Additionally, other pathways are being evaluated in both intrahepatic cholangiocarcinoma and other subtypes of biliary tract cancer, alongside targeting of the immune microenvironment. The growing knowledge of biliary tract cancer biology and molecular heterogeneity has paved the way for the development of new therapeutic approaches that will completely change the treatment paradigm for this disease in the near future. In this review, we review recently published data on the use of second-line therapy after progression with standard first-line therapy in patients with biliary cancer.

3 July 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ISIlya V. Savchenko
Ilya V. Savchenko
ISIvan S. Stilidi
Ivan S. Stilidi
IDIrina A. Dzhanyan
Irina A. Dzhanyan
EAElena Yu. Antonova
Elena Yu. Antonova
APAlexander N. Polyakov
Alexander N. Polyakov
ПНПоляков Александр Николаевич
Поляков Александр Николаевич
Aim. To evaluate the efficacy and toxicity of second-line polychemotherapy according to FOLFOX or FOLFIRI regimen in patients with biliary tract tumours after progression during first-line chemotherapy (CT). Materials and methods. The study is based on the analysis of retrospective and prospective data on the examination and treatment of 94 patients with biliary cancer of grades T1-4N0-2M0-1 followed-up and treated at the N.N. Blokhin National Medical Research Center of Oncology from 2015 to 2023. All patients were divided into 2 groups: Group 1 (FOLFOX, n=47) and Group 2 (FOLFIRI, n=47). In Group 1, patients received the recommended FOLFOX second-line CT regimen. Patients in Group 2 received FOLFIRI regimen. The endpoints were overall survival (OS) and incidence of grade 3-4 adverse events. Results. The study included 94 patients. In the FOLFOX group, the median OS was 13.0 months (1-year OS was 57.8±7.4%); for the FOLFIRI group, the median OS was 12.3 months (1-year OS was 54.4±7.3%). The toxicity profiles of FOLFOX and FOLFIRI were acceptable and consistent with those reported for the regimens. According to the grade 3–4 toxicity data, diarrhea was significantly more common in the FOLFIRI group (p=0.014), and neurotoxicity was more common in the FOLFOX group (p=0.006). During the second-line CT, the frequency of grade 1–4 toxicities in the groups did not differ: 18 (38.3%) events in the FOLFOX group and 19 (40.0%) events in the FOLFIRI group. Conclusion. Our results of evaluating the efficacy and toxicity of the second-line polychemotherapy regimens show that the FOLFOX and FOLFIRI CT regimens have equal efficacy in patients with advanced biliary tract cancer with a good performance according to the ECOG scale, who previously received the first-line therapy with a combination of gemcitabine with a platinum agent (cisplatin or oxaliplatin); also, our data demonstrate similar toxicity profiles of these regimens.

17 April 2023 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SCSvetlana Chulkova
Svetlana Chulkova
ESE. N. Sholokhova
E. N. Sholokhova
IPI. V. Poddubnaya
I. V. Poddubnaya
ISI. S. Stylidi
I. S. Stylidi
AEAngelina Egorova
Angelina Egorova
NTN. N. Tupitsyn
N. N. Tupitsyn
Backgraund. Currently, immunotherapy is firmly established in the standard of cancer treatment. The basis for the appointment of immunotherapy are immunological tumor markers, which include lymphoid infiltration, a detailed study of which has received increasing attention in the last decade. An undoubted interest is the study of lymphoid infiltration, not only depending on the morpho-clinical parameters of breast cancer (BC), but also on the immune system of the bone marrow.Aim. To evaluate the infiltration of the primary tumor by lymphocytes depending on the morpho-clinical characteristics of BC and immune responses in the bone marrow.Materials and methods. This study included 125 patients with BC who received treatment at the “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russia. Tumor stage II was prevailed, а moderate degree of differentiation (G2) was more often noted. The luminal BC – 67 %, non-luminal – 33 %. Immunophenotyping of the primary tumor: cryostat sections, ZEISS Axioscope luminescent microscope (Zeiss AG, Germany). CD45+, CD38+, T- and B-cell infiltration were assessed. Bone marrow: CD3+, CD4+, CD8+, CD19+, CD16+, CD56+ lymphocytes and their subpopulations were studied (FACSCanto II flow cytometer, Kaluza Analysis v2.1 program (Beckman Coulter, USA)).Results. CD45+ infiltration was noted in 50.5 % of cases (severe in 30 %, moderate – 26.4 %). CD8+ cells significantly infiltrated the tumor in 21.4 % of cases. CD38+ infiltration was observed in 40 %. In the non-luminal BC, severe CD45 infiltration was observed more frequently than in the luminal (33 % vs 26 %). CD38+ infiltration is expressed in non-luminal BC (p = 0.016). CD45+ infiltration was positively correlated with earlier stages (p = 0.071) more pronounced in infiltrative ductal BC, than in lobular BC: 59.2 % vs 20 % (p = 0.05). The content of CD45RO+cells in bone marrow in the luminal BC is higher than in the non-luminal: 37.3 ± 2.3 % vs 28 ± 2.8 % (p = 0.04). The number of CD19+CD38+ cells, on the contrary, is less: 24.2 ± 2 % vs 34.8 ± 6 % (p = 0.041). Tumor-infiltrating lymphocytes highly correlated with bone marrow lymphoid populations: CD38+ cells with NK-bone marrow cells; CD4+ cells with the B-precursors; CD8+cells with the B1-lymphocytes.Conclusion. Lymphoid infiltration of BC is associated with stage, tumor size, histological type and biological subtype. Intratumoral populations CD38+, CD4+, CD3+, CD8+ cells are in a negative correlation with bone marrow lymphoid populations.